AIP
CRSP icon

Ameritas Investment Partners’s CRISPR Therapeutics CRSP Stock Holding History

Ameritas Investment Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$356K Buy
7,475
+278
+4% +$14.7K 0.01% 957
2025
Q4 		$377K Buy
7,197
+282
+4% +$16.9K 0.01% 913
2025
Q3 		$448K Sell
6,915
-1,536
-18% -$88.2K 0.01% 859
2025
Q2 		$411K Buy
+8,451
New +$327K 0.01% 925

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameritas Investment Partners's CRSP Position: Q1 2026 in Review

Ameritas Investment Partners increased its CRISPR Therapeutics (CRSP) stake by 3.9% in Q1 2026, buying an estimated $14.7K and bringing the position to 7,475 shares worth $356K. The position accounts for 0.01% of the portfolio, ranked #957.

Ameritas Investment Partners first reported a position in CRSP in Q2 2025 and has held it in 4 quarters since. The position peaked at $448K in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Ameritas Investment Partners held 7,475 shares of CRISPR Therapeutics worth $356K as of Q1 2026.
  • Ameritas Investment Partners bought 278 CRISPR Therapeutics shares in Q1 2026, an estimated $14.7K.
  • CRISPR Therapeutics made up 0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #957 holding.
  • Ameritas Investment Partners first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Ameritas Investment Partners's CRISPR Therapeutics position peaked at $448K in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.